Sorafenib as treatment for relapsed or refractory pediatric acute myelogenous leukemia

Tanya C. Watt, Todd Cooper

Research output: Contribution to journalArticle

14 Citations (Scopus)

Abstract

The prognosis for children with acute myelogenous leukemia (AML) has improved with overall survival rates of up to 65% [Pui et al. J Clin Oncol 2011; 29: 551-565]. However, the cure rate for AML lags behind that of acute lymphoblastic leukemia. Advances in AML leukemogenesis are leading to refined risk stratification. FMS like tyrosine kinase 3 (FLT3) mutations are independently associated with a poor prognosis. Newer kinase inhibitors, including sorafenib, have shown promise in adult studies. We report three pediatric patients with relapsed AML who achieved a sustained remission with sorafenib. Further trials are necessary to understand the role of sorafenib in pediatric AML. Pediatr Blood Cancer 2012;59:756-757.

Original languageEnglish (US)
Pages (from-to)756-757
Number of pages2
JournalPediatric Blood and Cancer
Volume59
Issue number4
DOIs
StatePublished - Oct 2012

Fingerprint

Acute Myeloid Leukemia
Pediatrics
Therapeutics
Precursor Cell Lymphoblastic Leukemia-Lymphoma
Protein-Tyrosine Kinases
Phosphotransferases
Survival Rate
sorafenib
Mutation
Neoplasms

Keywords

  • AML
  • Pediatrics
  • Relapse
  • Sorafenib

ASJC Scopus subject areas

  • Oncology
  • Pediatrics, Perinatology, and Child Health
  • Hematology

Cite this

Sorafenib as treatment for relapsed or refractory pediatric acute myelogenous leukemia. / Watt, Tanya C.; Cooper, Todd.

In: Pediatric Blood and Cancer, Vol. 59, No. 4, 10.2012, p. 756-757.

Research output: Contribution to journalArticle

@article{66403f9d831e4a0f8d2abe150ed6d262,
title = "Sorafenib as treatment for relapsed or refractory pediatric acute myelogenous leukemia",
abstract = "The prognosis for children with acute myelogenous leukemia (AML) has improved with overall survival rates of up to 65{\%} [Pui et al. J Clin Oncol 2011; 29: 551-565]. However, the cure rate for AML lags behind that of acute lymphoblastic leukemia. Advances in AML leukemogenesis are leading to refined risk stratification. FMS like tyrosine kinase 3 (FLT3) mutations are independently associated with a poor prognosis. Newer kinase inhibitors, including sorafenib, have shown promise in adult studies. We report three pediatric patients with relapsed AML who achieved a sustained remission with sorafenib. Further trials are necessary to understand the role of sorafenib in pediatric AML. Pediatr Blood Cancer 2012;59:756-757.",
keywords = "AML, Pediatrics, Relapse, Sorafenib",
author = "Watt, {Tanya C.} and Todd Cooper",
year = "2012",
month = "10",
doi = "10.1002/pbc.23394",
language = "English (US)",
volume = "59",
pages = "756--757",
journal = "Pediatric Blood and Cancer",
issn = "1545-5009",
publisher = "Wiley-Liss Inc.",
number = "4",

}

TY - JOUR

T1 - Sorafenib as treatment for relapsed or refractory pediatric acute myelogenous leukemia

AU - Watt, Tanya C.

AU - Cooper, Todd

PY - 2012/10

Y1 - 2012/10

N2 - The prognosis for children with acute myelogenous leukemia (AML) has improved with overall survival rates of up to 65% [Pui et al. J Clin Oncol 2011; 29: 551-565]. However, the cure rate for AML lags behind that of acute lymphoblastic leukemia. Advances in AML leukemogenesis are leading to refined risk stratification. FMS like tyrosine kinase 3 (FLT3) mutations are independently associated with a poor prognosis. Newer kinase inhibitors, including sorafenib, have shown promise in adult studies. We report three pediatric patients with relapsed AML who achieved a sustained remission with sorafenib. Further trials are necessary to understand the role of sorafenib in pediatric AML. Pediatr Blood Cancer 2012;59:756-757.

AB - The prognosis for children with acute myelogenous leukemia (AML) has improved with overall survival rates of up to 65% [Pui et al. J Clin Oncol 2011; 29: 551-565]. However, the cure rate for AML lags behind that of acute lymphoblastic leukemia. Advances in AML leukemogenesis are leading to refined risk stratification. FMS like tyrosine kinase 3 (FLT3) mutations are independently associated with a poor prognosis. Newer kinase inhibitors, including sorafenib, have shown promise in adult studies. We report three pediatric patients with relapsed AML who achieved a sustained remission with sorafenib. Further trials are necessary to understand the role of sorafenib in pediatric AML. Pediatr Blood Cancer 2012;59:756-757.

KW - AML

KW - Pediatrics

KW - Relapse

KW - Sorafenib

UR - http://www.scopus.com/inward/record.url?scp=84864928986&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84864928986&partnerID=8YFLogxK

U2 - 10.1002/pbc.23394

DO - 10.1002/pbc.23394

M3 - Article

C2 - 22052552

AN - SCOPUS:84864928986

VL - 59

SP - 756

EP - 757

JO - Pediatric Blood and Cancer

JF - Pediatric Blood and Cancer

SN - 1545-5009

IS - 4

ER -